Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanable heritable hyperlipidemic rabbits

Hypertension Research

Volumn 31, Issue 6, 2008, Pages 1199-1208

  Imanishi, Toshio ^a   Ikejima, Hideyuki ^a   Tsujioka, Atsushi ^a   Kuroi, Akio ^a   Kobayashi, Katsunobu ^a   Shiomi, Masashi ^b   Muragaki, Yasuteru ^a   Mochizuki, Seiichi ^c   Goto, Masami ^c   Yoshida, Kiyoshi ^c   Akasaka, Takashi ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Angiotensin II type 1 receptor blocker; Endothelium; Nitrative stress; Nitric oxide; Statin

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PEROXYNITRITE; PITAVASTATIN; SUPEROXIDE; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BIOAVAILABILITY; BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESPONSE; EXPERIMENTAL ANIMAL; HEART INFARCTION; HISTOPATHOLOGY; HYPERLIPIDEMIA; MEAN ARTERIAL PRESSURE; MONOTHERAPY; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; RABBIT; THORACIC AORTA;

ACETYLCHOLINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL AVAILABILITY; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MYOCARDIAL INFARCTION; NITRIC OXIDE; QUINOLINES; RABBITS; REACTIVE OXYGEN SPECIES; TETRAZOLES; TYROSINE; VALINE;

EID: 48349117335     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.1199     Document Type: Article

References (32)

1. Libby P, Theroux P: Pathophysiology of coronary artery disease. Circulation 2005; 111: 3481-3488.
2. Kannel WB: Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000; 13: 3S-10S.
3. Ginsberg HN, Stalenhoef AF: The metabolic syndrome: targeting dyslipidemia to reduce coronary risk. J Cardiovasc Risk 2003; 10: 121-128.
4. Sowers JR: Effects of statins on the vasculature. Implications for aggressive lipid management in the cardiovascular metabolic syndrome. Am J Cardiol 2003; 91: 14B-22B.
5. Kjeldsen SE, Julius S: Hypertension mega-trials with cardiovascular and points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am Heart J 2004; 148: 747-754.
6. Mochizuki S, Miyasaka T, Goto M, et al: Measurement of acetylcholine-induced endothelium-derived nitric oxide in aorta using a newly developed catheter-type nitric oxide sensor. Biochem Biophys Res Commun 2003; 306: 505-508.
7. Neishi Y, Mochizuki S, Miyasaka T, et al: Evaluation of bioavailability of nitric oxide in coronary circulation by direct measurement of plasma nitric oxide concentration. Proc Natl Acad Sci U S A 2005; 102: 11456-11461.
8. Imanishi T, Kobayashi K, Kuroi A, et al: Effects of angiotensin II on NO bioavailability evaluate using a catheter-type NO sensor. Hypertension 2006; 48: 1058-1065.
9. Nickenig G: Should angiotensin II receptor blockers and statins be continued? Circulation 2004; 110: 1013-1020.
10. Suzuki H, Yamazaki H, Aoki T, et al: Lipid-lowering and antiatherosclerotic effect of NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in Watanabe heritable hyperlipidemic rabbits. Arzneimittelforschung 2000; 50: 995-1003.
11. Ter Steege JCA, Koster-Kamphuis L, V Straaten EA, et al: Nitrotyrosine in plasma of celiac disease patients as detected by a new sandwich ELISA. Free Radic Biol Med 1998; 25: 953-963.
12. Jang IK, Tearney GJ, MacNeill B, et al: In vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography. Circulation 2005; 111: 1551-1555.
13. Imanishi T, McBride J, Ho Q, O'Brien KD, Schwartz SM, Han DK: Expremiou of cellular FLICE-inhibitory protein in human coronary aeteries and in a rat vascular injury model. Am J Pathol 2000; 156: 125-137.
14. Balk EM, Karas RH, Jordan H$, Kupelnick B, Chew, P, Lau J: Effects of statins on vascular structure and function; a systemic review. Am J Med 2004; 117: 775-790.
15. O'Driscoll G, Green D, Rankin J, Stanton K, Taylor R: Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest 1997; 100: 678-684.
16. Cheetham C, Collis J, O'Driscoll G, Stanton K, Taylor R, Green D: Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. J Am Coll Cardiol 2000; 36: 1461-1466.
17. Hornig B, Lnadmesser V, Kohler C, et al: Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonist on bioavailability of nitric oxide in patients with coronary artery dhmsc: role of superoxide dismutase. Circulation 2001; 103: 799-805.
18. Tao L, Liu HR, Gao E, et al: Antioxidative, antinitrative, and vasculoprotective affects of a peroxisome proliferator-activated receptor-γ agonist in hypercholesterolemia. Circulation 2003; 108: 2805-2811.
19. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth umscle cells. Circ Res 1994; 74: 1141-1148.
20. Rajagopalan S, Kurz S, Munzel T, et al: Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J Clin Invest 1996; [b 97: 1916-1923.
21. Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM, Quinn MT: Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Natl Acad Sci USA 1997; 94: 14483-14488.
22. Warnholtz A, Nickenig G, Schulz E, et al: Increased NADH-oxidase-mediated superoxids production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 1999; 99: 2027-2033.
23. Griendling KK, FitzGerald GA. Oxisative stress and cardiovascular injury: Part I: basic mechanism and in vivo monitoring of ROS. Circulation 2003; 108: 1912-1916.
24. Landmesser U, Dikalov S, Price SR, et al: Oxidation of tetrahydropterin leads to uncoupling of endothelial cell nitric oxide synthesis in hypertension. J Clin Invest 2003; 111: 1201-1209.
25. Laursen JB, Somers M, Kurz S, et al: Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and istrahydrobiopterin. Circulation 2001; 103: 1282-1288.
26. Stuehr D, Pon S. Rosen GM: Oxygen reduction by nitric oxide synthases. J Biol Chem 2001; 276: 145333-145336.
27. Kawashima S, Yokoyama M: Dysfunction of endothelial nitric oxide synthase and atherosclesis. Arterioscler Thromb Vasc Biol 2004; 24: 998-1005.
28. Ozaki M, Kawashima S, Yamashika T, et al: Overexpression of endothelial nitric oxide synthase accelarates atherosclerotic lesion formation in apo E-deficient mice. J Clin Invest 2002; 110: 331-340.
29. Horiuchi V, Cui TX, Li Z, Li JM, Nakagami H, Iwai M: Fluvastatin enhances the inhibitory affects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal fotmation. Circulation 2003; 107: 106-112.
30. Li Z, Iwai M, Wu L, et al: Fluvastation enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis. Hypertension 2004; 44: 758-763.
31. Jang IK, Bouma BE, kang DH, et al: Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: comparison with intravascular ultrasound. J Am Coll Cardiol 2002; 39: 604-609.
32. Yabushita H, Bouma BE, Houser SL, et al: Characterization of human atherosclerosis by optical coherence tomography. Circulation 2002; 106: 1640-1645.